Eight Humira biosimilars have been launched, but payer formularies and interchangeability rules decide what dispenses.
Humira’s (adalimumab; AbbVie) patent exclusivity ended, and the market responded the way patent cliffs typically do, except this time, at least 8 distinct adalimumab biosimilars have launched, each with their own brand name, manufacturer, and—in several cases—its own formulation.1 For a pharmacist filling a prescription written simply for adalimumab, that used to mean 1 product. Now, it can mean any 1 of 8, and which one is actually covered depends entirely on which payer the patient carries.
Mohammed Chammout, PharmD, BCMTMS, is a clinical access and reimbursement specialist at Outcomes in Dearborn, Michigan, with experience in clinical coverage strategy, specialty pharmacy management, and prior authorization optimization. His practice focus includes medication access barriers and payer policy across primary care and specialty settings.
Amjevita (adalimumab-atto; Amgen), Cyltezo (adalimumab-adbm; Boehringer Ingelheim Pharmaceuticals), Hyrimoz (adalimumab-adaz; Sandoz), Yuflyma (adalimumab-aaty; Celltrion), Yusimry (adalimumab-aqvh; Coherus BioSciences), Abrilada (adalimumab-afzb; Pfizer), Hadlima (adalimumab-bwwd; Samsung Bioepis, Organon), and Simlandi (adalimumab-ryvk; Teva Pharmaceutials) are all biosimilars to reference adalimumab, but they are not interchangeable with one another. Some carry FDA interchangeability designation, meaning a pharmacist can substitute them for the reference product without prescriber sign-off where state law allows. Others do not carry that designation and require a new prescription to switch. Formulationals ovaries: Yuflyma launched as a high-concentration, citrate-free product, a genuine clinical differentiator for patients sensitive to injection-site reactions, while other biosimilars retain Humira's original concentration and formulation.2
Pricing spread across these products is dramatic, and it does not track with clinical value. Yuflyma launched at $6576.50 per month. Yusimry launched at $995 per carton of two 40-mg autoinjectors, a fraction of that cost.2 Two products, same active ingredient, same approved indications, but significantly different price points, because biosimilar pricing reflects manufacturer strategy and payer contracting, not differences in how well the drug works.
The 2 largest pharmacy benefit managers (PBMs), OptumRx and Express Scripts, independently selected the same 5 biosimilars for their primary formularies: both high- and low-list price versions of Amjevita, plus Cyltezo and Hyrimoz.3 That overlap might suggest some consolidation toward a standard set, but it does not hold across the industry. For example, the current medical policy for Blue Cross Blue Shield of Mississippi removed Humira from its medically necessary list entirely, designating only Hadlima and Simlandi as covered adalimumab options, while stating explicitly that Abrilada, Amjevita, Cyltezo, Hulio, Humira itself, Hyrimoz, and Idacio are not covered on any of its formularies at all.4
That is not a hypothetical example. It is a real, current policy from a real payer, and it means a prescription for “adalimumab” that would fill cleanly under an OptumRx plan could reject entirely under a different payer’s formulary, not because the patient doesn't qualify clinically, but because the specific brand written or dispensed isn't one that payer covers at all.
The practical result at the counter is a new category of rejection that has nothing to do with prior authorization criteria or step therapy, it is a product-selection mismatch. A prescriber's office may default to whichever adalimumab biosimilar their electronic health record system suggests first, without visibility into which specific product a given patient's payer actually prefers. The pharmacist is often the first person in the chain to discover them is match, at the point of dispensing, when the claim rejects.
Verifying the payer’s preferred product before dispensing, rather than after a rejection, is the single highest-leverage step available here. That means checking current formulary status for the specific patient’s plan, not relying on which biosimilar happens to be in stock or which one the pharmacy system defaults to first.
Even when a formulary-preferred biosimilar is identified, interchangeability status determines whether a pharmacist can substitute it for what was originally prescribed without going back to the prescriber. Not every adalimumab biosimilar carries FDA interchangeability designation, and state substitution laws still govern whether and how that substitution can happen at the pharmacy level. Confirming interchangeability status before substituting, not after, avoids a second category of avoidable delay.
Adalimumab is not the last biologic to face this exact dynamic. Ustekinumab (Stelara; ) followed a similar path, now facing more than a dozen biosimilars, including PBM-affiliated private-label versions alongside independently marketed ones.5 As more biologics lose exclusivity over the next several years, this same pattern, multiple products, uneven interchangeability status,
payer-specific formulary fragmentation, is likely to repeat across other drug classes. Building the habit of verifying payer-specific product preference before dispensing, rather than assuming any adalimumab biosimilar will do, is a skill that will apply well beyond this 1 drug.
